
Earnings Insights
AI-generated analysis of quarterly earnings, concall highlights, and financial performance across Indian listed companies.
How to use these insights
Each article is built from earnings call transcripts and structured rank signals. Start with the latest summary, then open the stock page for the full company view, the concall page for quarter-by-quarter commentary, and the rankings dashboard to compare peers.
Happiest Minds Technologies Q3 FY26 earnings call: Revenue & Margins | Arthneeti
Q3 FY26
Adjusted PAT has improved, indicating healthy earnings growth, with Q3 adjusted PAT margin around 11.6%. Key concall takeaways from Happiest Minds Technologies…
5 Aug 2026
Happiest Minds Technologies Q1 FY26 earnings call: Revenue & Margins | Arthneeti
Q1 FY26
EBITDA margin stood at 21.4% this quarter with 12.9% sequential growth; margin improvement strategies include utilization improvement and sales engine…
5 Aug 2026
Happiest Minds Technologies Q3 FY25 earnings call: Revenue & Margins | Arthneeti
Q3 FY25
Cash EPS showed good year-over-year growth (12.6% last quarter), with annualized Cash EPS at ₹24.6. Key concall takeaways from Happiest Minds Technologies…
5 Aug 2026
Borosil Q3 FY26 earnings call: Revenue & Margins | Arthneeti
Q3 FY26
Glassware production is near 90% utilization, with plans for brownfield expansion of 50% capacity in existing facilities. Key concall takeaways from Borosil…
5 Aug 2026
Borosil Q1 FY26 earnings call: Revenue & Margins | Arthneeti
Q1 FY26
No immediate expansion of new production facilities planned; management prefers to wait until demand justifies INR 200 crore CAPEX. Key concall takeaways from…
5 Aug 2026
Borosil Q4 FY25 earnings call: Revenue & Margins | Arthneeti
Q4 FY25
Historically, the company has achieved a sales CAGR of approximately 23.5% from 2018 to 2025. Key concall takeaways from Borosil Ltd's Q4 FY25 earnings call…
5 Aug 2026
Max Healthcare Institute Q2 FY26 earnings call: Revenue & Margins | Arthneeti
Q2 FY26
Network gross revenue grew 24% YoY to INR 5,266 crore in the recent quarter, indicating strong ongoing growth. Key concall takeaways from Max Healthcare…
5 Aug 2026
Max Healthcare Institute Q1 FY26 earnings call: Revenue & Margins | Arthneeti
Q1 FY26
Max Healthcare reported a strong 27% year-on-year revenue growth in Q1 FY '26, driven by successful hospital acquisitions and integrations. Key concall…
5 Aug 2026
Max Healthcare Institute Q4 FY25 earnings call: Revenue & Margins | Arthneeti
Q4 FY25
FY '25 revenue saw a 26% YoY growth and 22% growth in EBITDA. Key concall takeaways from Max Healthcare Institute Ltd's Q4 FY25 earnings call — and how it…
5 Aug 2026
Rossari Biotech Q3 FY26 earnings call: Revenue & Margins | Arthneeti
Q3 FY26
Exports have been growing strongly and contributed about 30% of turnover in the 9 months ended FY26. Key concall takeaways from Rossari Biotech Ltd's Q3 FY26…
5 Aug 2026
Mindspace Business Parks REIT Q1 FY26 earnings call: Revenue & Margins | Arthneeti
Q1 FY26
Mindspace REIT delivered strong Q1 FY'26 results with 24.2% YoY NOI growth and 21.4% revenue growth. Key concall takeaways from Mindspace Business Parks REIT's…
5 Aug 2026
Mindspace Business Parks REIT Q3 FY25 earnings call: Revenue & Margins | Arthneeti
Q3 FY25
167 crores, implying an 8.2% growth to overall NOI. Key concall takeaways from Mindspace Business Parks REIT's Q3 FY25 earnings call — and how it ranks against…
5 Aug 2026
Rossari Biotech Q2 FY26 earnings call: Revenue & Margins | Arthneeti
Q2 FY26
Revenue growth in Q2 FY26 was strong at 18% YoY, driven largely by volume increases across all verticals (HPPC, TSC, AHN). Key concall takeaways from Rossari…
5 Aug 2026
Rossari Biotech Q1 FY26 earnings call: Revenue & Margins | Arthneeti
Q1 FY26
Volume growth in exports has been 11% YoY despite temporary disruptions, indicating robust demand. Key concall takeaways from Rossari Biotech Ltd's Q1 FY26…
5 Aug 2026
Rossari Biotech Q4 FY25 earnings call: Revenue & Margins | Arthneeti
Q4 FY25
Consumer and Institutional businesses grew 67% YoY to Rs. Key concall takeaways from Rossari Biotech Ltd's Q4 FY25 earnings call — and how it ranks against…
5 Aug 2026
Altius Telecom Infrastructure Trust Q2 FY26 earnings call: Revenue & Margins | Arthneeti
Q2 FY26
Growth fueled by contractual escalations (~2.5% annual escalations), organic expansion through increased tower deployment and tenancy additions, and strategic…
5 Aug 2026
Cohance Lifesciences Q3 FY26 earnings call: Revenue & Margins | Arthneeti
Q3 FY26
Free cash flow generation remains resilient, with INR175 crore generated in the first nine months of FY '26, supporting sound balance sheet and steady capital…
5 Aug 2026
Ujjivan Small Finance Bank Q3 FY26 earnings call: Revenue & Margins | Arthneeti
Q3 FY26
. Key concall takeaways from Ujjivan Small Finance Bank Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
5 Aug 2026
Hitachi Energy Q3 FY26 earnings call: Revenue & Margins | Arthneeti
Q3 FY26
29,872 crores), supporting sustained revenue growth. Key concall takeaways from Hitachi Energy's Q3 FY26 earnings call — and how it ranks against sector peers.
5 Aug 2026
SBI Cards & Payment Services Q3 FY26 earnings call: Revenue & Margins | Arthneeti
Q3 FY26
Growth in spends remains good (~14-15%), with focus on improving quality of spend and increasing credit card portfolio. Key concall takeaways from SBI Cards &…
5 Aug 2026
Arthneeti Pro · Annual
Every earnings call this season,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access